Tsanyang Jake Liang

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9013963/publications.pdf Version: 2024-02-01

109 papers	14,632 citations	23567 58 h-index	24982 109 g-index
112	112	112	14288
all docs	docs citations	times ranked	citing authors

TSANVANC LAKE LIANC

#	Article	IF	CITATIONS
1	Production of infectious hepatitis C virus in tissue culture from a cloned viral genome. Nature Medicine, 2005, 11, 791-796.	30.7	2,561
2	Specific and Nonhepatotoxic Degradation of Nuclear Hepatitis B Virus cccDNA. Science, 2014, 343, 1221-1228.	12.6	774
3	Pathogenesis, Natural History, Treatment, and Prevention of Hepatitis C. Annals of Internal Medicine, 2000, 132, 296.	3.9	764
4	A pilot study of pioglitazone treatment for nonalcoholic steatohepatitis. Hepatology, 2004, 39, 188-196.	7.3	679
5	Hepatitis B Reactivation Associated With Immune Suppressive and Biological Modifier Therapies: Current Concepts, Management Strategies, and Future Directions. Gastroenterology, 2017, 152, 1297-1309.	1.3	442
6	Current and Future Therapies for Hepatitis C Virus Infection. New England Journal of Medicine, 2013, 368, 1907-1917.	27.0	418
7	Systematic Review: The Effect of Preventive Lamivudine on Hepatitis B Reactivation during Chemotherapy. Annals of Internal Medicine, 2008, 148, 519.	3.9	407
8	The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease. Hepatology, 2010, 52, 894-903.	7.3	403
9	Progression of fibrosis in chronic hepatitis C. Gastroenterology, 2003, 124, 97-104.	1.3	368
10	Hepatitis C Virus Structural Proteins Assemble into Viruslike Particles in Insect Cells. Journal of Virology, 1998, 72, 3827-3836.	3.4	345
11	A global scientific strategy to cure hepatitis B. The Lancet Gastroenterology and Hepatology, 2019, 4, 545-558.	8.1	342
12	A genome-wide genetic screen for host factors required for hepatitis C virus propagation. Proceedings of the National Academy of Sciences of the United States of America, 2009, 106, 16410-16415.	7.1	333
13	Present and future therapies of hepatitis B: From discovery to cure. Hepatology, 2015, 62, 1893-1908.	7.3	269
14	Natural Killer Cells Are Polarized Toward Cytotoxicity in Chronic Hepatitis C in an Interferon-Alfa–Dependent Manner. Gastroenterology, 2010, 138, 325-335.e2.	1.3	243
15	Hepatic gene expression during treatment with peginterferon and ribavirin: Identifying molecular pathways for treatment response. Hepatology, 2007, 46, 1548-1563.	7.3	242
16	HCV Infection Induces a Unique Hepatic Innate Immune Response Associated With Robust Production of Type III Interferons. Gastroenterology, 2012, 142, 978-988.	1.3	241
17	Pathogenesis of hepatitis C—associated hepatocellular carcinoma. Gastroenterology, 2004, 127, S62-S71.	1.3	203
18	17â€Beta Hydroxysteroid Dehydrogenase 13Âls a Hepatic Retinol Dehydrogenase Associated With Histological Features of Nonalcoholic Fatty Liver Disease. Hepatology, 2019, 69, 1504-1519.	7.3	200

#	Article	IF	CITATIONS
19	Hepatitis B virus–induced lipid alterations contribute to natural killer T cell–dependent protective immunity. Nature Medicine, 2012, 18, 1060-1068.	30.7	198
20	Hepatitis C virus infection activates an innate pathway involving IKK-α in lipogenesis and viral assembly. Nature Medicine, 2013, 19, 722-729.	30.7	167
21	Immunization with hepatitis C virus-like particles results in control of hepatitis C virus infection in chimpanzees. Proceedings of the National Academy of Sciences of the United States of America, 2007, 104, 8427-8432.	7.1	157
22	ls SARS-CoV-2 Also an Enteric Pathogen With Potential Fecal–Oral Transmission? A COVID-19 Virological and Clinical Review. Gastroenterology, 2020, 159, 53-61.	1.3	157
23	Immunization with hepatitis C virus-like particles protects mice from recombinant hepatitis C virus-vaccinia infection. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 6753-6758.	7.1	152
24	Current progress in development of hepatitis C virus vaccines. Nature Medicine, 2013, 19, 869-878.	30.7	144
25	Ribavirin potentiates interferon action by augmenting interferon-stimulated gene induction in hepatitis C virus cell culture models. Hepatology, 2011, 53, 32-41.	7.3	140
26	Engrafted human stem cell–derived hepatocytes establish an infectious HCV murine model. Journal of Clinical Investigation, 2014, 124, 4953-4964.	8.2	131
27	Hepatitis C virus treatment in the real world: optimising treatment and access to therapies: TableÂ1. Gut, 2015, 64, 1824-1833.	12.1	128
28	Hepatitis B virus evades innate immunity of hepatocytes but activates cytokine production by macrophages. Hepatology, 2017, 66, 1779-1793.	7.3	128
29	Associations of chemokine system polymorphisms with clinical outcomes and treatment responses of chronic hepatitis C. Gastroenterology, 2003, 124, 352-360.	1.3	124
30	Repurposing of the antihistamine chlorcyclizine and related compounds for treatment of hepatitis C virus infection. Science Translational Medicine, 2015, 7, 282ra49.	12.4	118
31	Interaction of Hepatitis C Virus-Like Particles and Cells: a Model System for Studying Viral Binding and Entry. Journal of Virology, 2002, 76, 9335-9344.	3.4	113
32	The Application and Mechanism of Action of Ribavirin in Therapy of Hepatitis C. Antiviral Chemistry and Chemotherapy, 2012, 23, 1-12.	0.6	109
33	Ribavirin Improves Early Responses to Peginterferon Through Improved Interferon Signaling. Gastroenterology, 2010, 139, 154-162.e4.	1.3	108
34	Immunization with Hepatitis C Virus-Like Particles Induces Humoral and Cellular Immune Responses in Nonhuman Primates. Journal of Virology, 2004, 78, 6995-7003.	3.4	106
35	Human stem cell-derived hepatocytes as a model for hepatitis B virus infection, spreading and virus-host interactions. Journal of Hepatology, 2017, 66, 494-503.	3.7	105
36	An in vitro model of hepatitis C virion production. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 2579-2583.	7.1	104

#	Article	IF	CITATIONS
37	Therapy of Hepatitis C — Back to the Future. New England Journal of Medicine, 2014, 370, 2043-2047.	27.0	102
38	Integrative Functional Genomics of Hepatitis C Virus Infection Identifies Host Dependencies in Complete Viral Replication Cycle. PLoS Pathogens, 2014, 10, e1004163.	4.7	101
39	Direct, Interferon-Independent Activation of the CXCL10 Promoter by NF-κB and Interferon Regulatory Factor 3 during Hepatitis C Virus Infection. Journal of Virology, 2014, 88, 1582-1590.	3.4	96
40	Production of Infectious Hepatitis C Virus of Various Genotypes in Cell Cultures. Journal of Virology, 2007, 81, 4405-4411.	3.4	95
41	Hepatitis C virus–like particles induce virus-specific humoral and cellular immune responses in mice. Hepatology, 2001, 34, 417-423.	7.3	90
42	Inhibition of Cellular Proteasome Activities Enhances Hepadnavirus Replication in an HBX-Dependent Manner. Journal of Virology, 2004, 78, 4566-4572.	3.4	90
43	Development of Direct-acting Antiviral and Host-targeting Agents for Treatment of Hepatitis B Virus Infection. Gastroenterology, 2019, 156, 311-324.	1.3	85
44	Maintenance therapy with ribavirin in patients with chronic hepatitis C who fail to respond to combination therapy with interferon alfa and ribavirin. Hepatology, 2003, 38, 66-74.	7.3	83
45	Hepatitis C $\hat{a} \in \hat{a}$ identifying patients with progressive liver injury. Hepatology, 2006, 43, S194-S206.	7.3	82
46	Scavenger Receptor Class B Is Required for Hepatitis C Virus Uptake and Cross-Presentation by Human Dendritic Cells. Journal of Virology, 2008, 82, 3466-3479.	3.4	79
47	Amphipathic DNA Polymers Inhibit Hepatitis C Virus Infection by Blocking Viral Entry. Gastroenterology, 2009, 137, 673-681.	1.3	78
48	Reactivation of Hepatitis B During Immunosuppressive Therapy: Potentially Fatal Yet Preventable. Annals of Internal Medicine, 2012, 156, 743.	3.9	74
49	Hepatic differentiation of human pluripotent stem cells in miniaturized format suitable for high-throughput screen. Stem Cell Research, 2016, 16, 640-650.	0.7	74
50	Antibodies Against Hepatitis C Virus–Like Particles and Viral Clearance in Acute and Chronic Hepatitis C. Hepatology, 2000, 32, 610-617.	7.3	72
51	Structural Features of Envelope Proteins on Hepatitis C Virus-like Particles as Determined by Anti-envelope Monoclonal Antibodies and CD81 Binding. Virology, 2002, 298, 124-132.	2.4	71
52	Inhibition of Hepatitis C Virus-Like Particle Binding to Target Cells by Antiviral Antibodies in Acute and Chronic Hepatitis C. Journal of Virology, 2004, 78, 9030-9040.	3.4	70
53	Experimental models of hepatitis B and C — new insights and progress. Nature Reviews Gastroenterology and Hepatology, 2016, 13, 362-374.	17.8	70
54	Cellular microRNA networks regulate host dependency of hepatitis C virus infection. Nature Communications, 2017, 8, 1789.	12.8	70

#	Article	IF	CITATIONS
55	Vaccine Development for Hepatitis C. Seminars in Liver Disease, 2000, 20, 211-226.	3.6	67
56	Dynamic Interaction of Stress Granules, DDX3X, and IKK-α Mediates Multiple Functions in Hepatitis C Virus Infection. Journal of Virology, 2015, 89, 5462-5477.	3.4	67
57	Src Homology 3 Domain of Hepatitis C Virus NS5A Protein Interacts With Bin1 and Is Important for Apoptosis and Infectivity. Gastroenterology, 2006, 130, 794-809.	1.3	62
58	Hepatitis C virus JFH-1 strain infection in chimpanzees is associated with low pathogenicity and emergence of an adaptive mutation. Hepatology, 2008, 48, 732-740.	7.3	56
59	Induction of Sterilizing Immunity against West Nile Virus (WNV), by Immunization with WNVâ€Like Particles Produced in Insect Cells. Journal of Infectious Diseases, 2004, 190, 2104-2108.	4.0	51
60	Cryo-electron microscopy and three-dimensional reconstructions of hepatitis C virus particles. Virology, 2007, 367, 126-134.	2.4	51
61	Mouse models for the study of HCV infection and virus–host interactions. Journal of Hepatology, 2008, 49, 134-142.	3.7	51
62	Effect of ribavirin on viral kinetics and liver gene expression in chronic hepatitis C. Gut, 2014, 63, 161-169.	12.1	51
63	Hepatitis C virus depends on E-cadherin as an entry factor and regulates its expression in epithelial-to-mesenchymal transition. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 7620-7625.	7.1	50
64	Combination Therapy for Hepatitis C Infection. New England Journal of Medicine, 1998, 339, 1549-1550.	27.0	48
65	Hepatitis C virus–like particles combined with novel adjuvant systems enhance virus-specific immune responses. Hepatology, 2003, 37, 52-59.	7.3	48
66	Infection of Hepatocytes With HCV Increases Cell Surface Levels of Heparan Sulfate Proteoglycans, Uptake of Cholesterol and Lipoprotein, and Virus Entry by Up-regulating SMAD6 and SMAD7. Gastroenterology, 2017, 152, 257-270.e7.	1.3	43
67	Hepatitis B Virus Deregulates the Cell Cycle To Promote Viral Replication and a Premalignant Phenotype. Journal of Virology, 2018, 92, .	3.4	43
68	What is the future of ribavirin therapy for hepatitis C?. Antiviral Research, 2014, 104, 34-39.	4.1	41
69	Baseline Intrahepatic and Peripheral Innate Immunity are Associated with Hepatitis C Virus Clearance During Directâ€Acting Antiviral Therapy. Hepatology, 2018, 68, 2078-2088.	7.3	38
70	Diminished hepatic IFN response following HCV clearance triggers HBV reactivation in coinfection. Journal of Clinical Investigation, 2020, 130, 3205-3220.	8.2	38
71	Both innate and adaptive immunity mediate protective immunity against hepatitis C virus infection in chimpanzees. Hepatology, 2011, 54, 1135-1148.	7.3	37
72	Novel Function of CD81 in Controlling Hepatitis C Virus Replication. Journal of Virology, 2010, 84, 3396-3407.	3.4	35

#	Article	IF	CITATIONS
73	Hepatitis B Surface Antigen Activates Unfolded Protein Response in Forming Ground Glass Hepatocytes of Chronic Hepatitis B. Viruses, 2019, 11, 386.	3.3	35
74	Modeling PNPLA3â€Associated NAFLD Using Humanâ€Induced Pluripotent Stem Cells. Hepatology, 2021, 74, 2998-3017.	7.3	35
75	Genetic Immunization of Wild-Type and Hepatitis C Virus Transgenic Mice Reveals a Hierarchy of Cellular Immune Response and Tolerance Induction against Hepatitis C Virus Structural Proteins. Journal of Virology, 2001, 75, 12121-12127.	3.4	30
76	Novel Cell-Based Hepatitis C Virus Infection Assay for Quantitative High-Throughput Screening of Anti-Hepatitis C Virus Compounds. Antimicrobial Agents and Chemotherapy, 2014, 58, 995-1004.	3.2	30
77	Discovery, Optimization, and Characterization of Novel Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. Journal of Medicinal Chemistry, 2016, 59, 841-853.	6.4	30
78	Monoclonal Antibodies with Broad Specificity for Hepatitis C Virus Hypervariable Region 1 Variants Can Recognize Viral Particles. Journal of Immunology, 2001, 167, 3878-3886.	0.8	29
79	Ribavirin improves the IFN-γ response of natural killer cells to IFN-based therapy of hepatitis C virus infection. Hepatology, 2014, 60, 1160-1169.	7.3	26
80	Rhesus iPSC Safe Harbor Gene-Editing Platform for Stable Expression of Transgenes in Differentiated Cells of All Germ Layers. Molecular Therapy, 2017, 25, 44-53.	8.2	26
81	N-Myc Downstream-Regulated Gene 1 Restricts Hepatitis C Virus Propagation by Regulating Lipid Droplet Biogenesis and Viral Assembly. Journal of Virology, 2018, 92, .	3.4	24
82	High-Throughput Screening, Discovery, and Optimization To Develop a Benzofuran Class of Hepatitis C Virus Inhibitors. ACS Combinatorial Science, 2015, 17, 641-652.	3.8	23
83	Controlled Human Infection Model — Fast Track to HCV Vaccine?. New England Journal of Medicine, 2021, 385, 1235-1240.	27.0	22
84	In vivo adaptation of hepatitis C virus in chimpanzees for efficient virus production and evasion of apoptosis. Hepatology, 2011, 54, 425-433.	7.3	21
85	MicroRNA-135a Modulates Hepatitis C Virus Genome Replication through Downregulation of Host Antiviral Factors. Virologica Sinica, 2019, 34, 197-210.	3.0	19
86	Evaluation of antiviral drug synergy in an infectious HCV system. Antiviral Therapy, 2016, 21, 595-603.	1.0	18
87	Chlorcyclizine Inhibits Viral Fusion of Hepatitis C Virus Entry by Directly Targeting HCV Envelope Glycoprotein 1. Cell Chemical Biology, 2020, 27, 780-792.e5.	5.2	18
88	Nâ€Terminal PreS1 Sequence Regulates Efficient Infection of Cellâ€Culture–Generated Hepatitis B Virus. Hepatology, 2021, 73, 520-532.	7.3	17
89	Discovery of Small Molecule Entry Inhibitors Targeting the Fusion Peptide of SARS-CoV-2 Spike Protein. ACS Medicinal Chemistry Letters, 2021, 12, 1267-1274.	2.8	16
90	Development of an Aryloxazole Class of Hepatitis C Virus Inhibitors Targeting the Entry Stage of the Viral Replication Cycle. Journal of Medicinal Chemistry, 2017, 60, 6364-6383.	6.4	12

#	Article	IF	CITATIONS
91	Hepatitis C Virus Infection Induces Hepatic Expression of NF-κB-Inducing Kinase and Lipogenesis by Downregulating miR-122. MBio, 2019, 10, .	4.1	12
92	Hepatitis B virus – recent therapeutic advances and challenges to cure. Journal of Hepatology, 2020, 73, 694-695.	3.7	12
93	Infection courses, virological features and IFN-α responses of HBV genotypes in cell culture and animal models. Journal of Hepatology, 2021, 75, 1335-1345.	3.7	12
94	Preclinical Pharmacological Development of Chlorcyclizine Derivatives for the Treatment of Hepatitis C Virus Infection. Journal of Infectious Diseases, 2018, 217, 1761-1769.	4.0	11
95	TM6SF2 Promotes Lipidation and Secretion of Hepatitis C Virus in Infected Hepatocytes. Gastroenterology, 2018, 155, 1923-1935.e8.	1.3	11
96	Genetically edited hepatic cells expressing the NTCP-S267F variant are resistant to hepatitis B virus infection. Molecular Therapy - Methods and Clinical Development, 2021, 23, 597-605.	4.1	11
97	Targeting the Fusion Process of SARS-CoV-2 Infection by Small Molecule Inhibitors. MBio, 2022, 13, e0323821.	4.1	11
98	Fluoxazolevir inhibits hepatitis C virus infection in humanized chimeric mice by blocking viral membrane fusion. Nature Microbiology, 2020, 5, 1532-1541.	13.3	10
99	Identification of novel anti-hepatitis C virus agents by a quantitative high throughput screen in a cell-based infection assay. Antiviral Research, 2015, 124, 20-29.	4.1	9
100	A dual conditional CRISPR-Cas9 system to activate gene editing and reduce off-target effects in human stem cells. Molecular Therapy - Nucleic Acids, 2022, 28, 656-669.	5.1	9
101	Single Strain Isolation Method for Cell Culture-Adapted Hepatitis C Virus by End-Point Dilution and Infection. PLoS ONE, 2014, 9, e98168.	2.5	7
102	A randomized, proof-of-concept clinical trial on repurposing chlorcyclizine for the treatment of chronic hepatitis C. Antiviral Research, 2019, 163, 149-155.	4.1	6
103	Discovery and characterization of a novel HCV inhibitor targeting the late stage of HCV life cycle. Antiviral Therapy, 2019, 24, 371-381.	1.0	5
104	Hepatitis B: a new weapon against an old enemy. Nature Medicine, 2021, 27, 1672-1673.	30.7	5
105	Metabolic Profiling Reveals Aggravated Non-Alcoholic Steatohepatitis in High-Fat High-Cholesterol Diet-Fed Apolipoprotein E-Deficient Mice Lacking Ron Receptor Signaling. Metabolites, 2020, 10, 326.	2.9	3
106	Border Control in Hepatitis C Virus Infection: Inhibiting Viral Entry. ACS Infectious Diseases, 2015, 1, 416-419.	3.8	2
107	Discovery and Optimization of a 4-Aminopiperidine Scaffold for Inhibition of Hepatitis C Virus Assembly. Journal of Medicinal Chemistry, 2021, 64, 9431-9443.	6.4	2
108	Coronavirus Disease-19 Has Come Home to Roost in Gastroenterology. Gastroenterology, 2020, 159, 36-38.	1.3	1

#	Article	IF	CITATIONS
109	Stem cell-derived HCV infection systems illustrate the bright future of human hepatocyte research. Gut, 2020, 69, 1550-1551.	12.1	0